Bioise Co., Ltd. (CEO Kim Seong-cheon) will participate in ‘BIO KOREA 5 (Bio Korea 10)’ held at COEX, Seoul for 12 days from Wednesday, May 3th to Friday, May 2023th and demonstrate RNA-centered protein synthesis system. The ‘RNA-CFS platform’ and the genome proteome analysis system SBI (System Biology Innovator) were introduced.
Biois is a bio venture established in 2013. It is known as a diagnostic device company, but has a history of researching ribonucleic acid (RNA) based on aptamers since the beginning of its establishment. After the pandemic, as the potential for RNA increased, we began developing it more actively, and as a result, we acquired a domestic patent in February under the name ‘Cell-free compositions, cells, and methods for transcription-translation for producing RNA of interest.’ did.
In addition, BioIS, which is attracting attention in the field of precision medicine by successfully developing and commercializing premium biopharmaceuticals that are difficult to manufacture in cells and SBI (System Biology Innovator), which analyzes the genome and proteome simultaneously, is developing high-performance biomolecules through this exhibition. ·Introduced in detail the proprietary technology for manufacturing ‘RNA-CFS’ (Cell-Free System) and SBI technology.
RNA-CFS is a synthetic biology that develops and manufactures biopharmaceuticals that are difficult to express in cells, and through this, cell-free systems and pneumococcal conjugate vaccines can be commercialized. This is because transformation and fusion is possible from the DNA-centered protein synthesis system (CFPS) to the RNA-centered protein synthesis system (RNA-CFS). This made it possible to produce RNA in large quantities.
SBI (System Biology Innovator), a proprietary technology that produces proteome and genome information and analyzes it with artificial intelligence to discover biomarkers, is a genome proteome analysis system that simultaneously analyzes the blood genome and proteome and predicts clinical information based on artificial intelligence.
An official said, “The reality is that RNA production technology is all using overseas technology, so it is limited to contract manufacturing (CMO) in Korea, but it is significant that our company has secured its own technology. Recently, we began attracting investment for our production plant and began a full-fledged scale-up. He revealed his future plans, saying, “We plan to list on the KOSDAQ (IPO) as early as next year.”
Meanwhile, ‘BIO KOREA 18’, which celebrated its 2023th anniversary this year, was hosted by the Korea Health Industry Development Institute and Chungcheongbuk-do. BIO KOREA, which has been striving to improve the global status and sustainable growth of the Korean health industry since 2006, is solidifying its position as Korea’s representative biohealth international convention with the participation of world-class scholars and business experts every year. BIO KOREA 2023, in collaboration with companies related to the health industry such as domestic and foreign bio, pharmaceuticals, medical devices, cosmetics, and food, as well as interested companies and institutions such as consulting, academia, and related organizations, will be held through various programs such as conferences, business partnering, exhibitions, and investment fairs. It goes on.